Adherence with tobramycin inhaled solution and health care utilization

Abstract

BackgroundAdherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.MethodsWe analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories.ResultsAmong 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768).ConclusionsUse of TIS did not reflect recommended guidelines and may impact other health care utilization.

Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

“…In the context of a clinical trial setting, the patients' adherence is generally high, whereas in the real-world, rates of adherence and persistence rates are much lower and the efficacy of a drug can be therefore decreased [149,152]. In addition, it is important to explore how patient satisfaction due to new delivery systems can be translated in real-life increased compliance, reduced treatment burden and better clinical outcomes.…”

Adherence to infection prevention and control guidelines: A vignette-based study of decision-making and risk-taking in young adults with cystic fibrosis

“…Whilst non-adherence to CF treatments is well-reported and linked to negative health outcomes [5][6][7][8][9] , adherence to IPC recommendations is less well-understood. Patient rates of avoiding contact with other people with CF are reported to be low (21%-27%), particularly in young adults 10,11 .…”

Adherence of Subjects With Cystic Fibrosis to Their Home Program: A Systematic Review

“…[15][16][17] Briesacher et al 18 demonstrated both a 60% decrease in the risk of hospitalization for people who were adherent to their treatment regimen and a relationship between low usage of chronic medications and increased exacerbations requiring intravenous therapy. Improving patient outcomes rests, in part, on increasing adherence to chronic therapies, and identifying reasons for non-adherence to treatment is important.…”